Brexucabtagene autoleucel (new indication: acute lymphoblastic leukemia, patients aged ≥ 26 years)

Subject:

• Active Substance: Brexucabtagene autoleucel
• Name: Tecartus®
• Therapeutic area: Acute lymphoblastic leukemia
• Pharmaceutical company: Gilead Sciences GmbH

Time table:

• Start: 01.10.2022
• Final decision by G-BA: 16.03.2023

Final decision:

• Hint for a non-quantifiable additional benefit (orphan drug)